Hidradenitis Suppurativa

James Del Rosso, DO; April Armstrong, MD, MPH; Mark Nestor, MD, PhD; Mark Lebwohl, MD; Linda Stein Gold, MD; and Darrell Rigel, MD, MS, presented some of the biggest updates in dermatology to close out the year.

CO₂ laser treatment significantly enhances quality of life for hidradenitis suppurativa patients, showing promising outcomes in a large prospective study.

Emerging biologic combinations may open a new therapeutic frontier for severe hidradenitis suppurativa (HS) that fails to respond to conventional and single-pathway biologics.

This review of the latest dermatologic studies highlights new research on hidradenitis suppurativa, including associated pediatric comorbidities, CO2 laser treatment, impact on sexual health, and more.

While VELA-1 achieved statistical significance under all analyses, VELA-2 narrowly missed its composite primary endpoint due to higher-than-expected placebo outcomes.

Many HS patients still require more aggressive or advanced treatments due to incomplete response to current options.

Sanofi's brivekimig shows promising phase 2a results for hidradenitis suppurativa (HS), offering hope for effective treatment options at EADV Congress 2025.

At EADV 2025, UCB presented new long-term data demonstrating bimekizumab’s durable efficacy and a consistent safety profile over extended treatment.

STOP-HS1 and STOP-HS2 phase 3 trials showed nearly 60% of patients achieving HiSCR50 by week 24, according to a presentation at EADV 2025.

HS management is shifting toward earlier diagnosis and intervention to prevent long-term scarring and disability.

Research shows it can take 7 to 10 years for individuals with HS to receive an accurate diagnosis.

Katrina Lee, MD, discussed innovative strategies and challenges in managing HS at the Dermatology Innovation Symposium, emphasizing early intervention and comprehensive care.

A recent HS Summit hosted by UCB brought together clinicians and patient advocates to strengthen research and awareness efforts.

Andrade's inspiring journey highlights the challenges of HS and the transformative impact of clinical trials.

Steven Daveluy, MD, highlighted lack of awareness and early misdiagnosis as major barriers to effective HS care.

Our July cover story explores effective treatments for hidradenitis suppurativa, including procedural interventions and advanced therapies that enhance patient quality of life.

Both regulatory-approved and pipeline treatments for moderate to severe HS demonstrate comparable efficacy and safety, offering hope for patients often dissatisfied with current treatment options.

A global survey reveals the significant psychosocial and financial burdens of hidradenitis suppurativa, highlighting the need for improved patient care and treatment options.

At SCALE 2025, Christina Feser, DO, FAAD, FAOCD, spotlighted the rapidly expanding pipeline of diverse therapies for patients with HS.

At RAD 2025, Matthew Zirwas, MD, outlined 2 upcoming shifts in dermatology: the emergence of povorcitinib for hidradenitis suppurativa and the anticipated generic availability of tofacitinib.

Adam Friedman, MD, FAAD, discusses the growing need for psychosocial support in hidradenitis suppurativa care and HS Connect’s role in closing the gap.

Celltrion's Yuflyma gains full FDA interchangeability, enhancing patient access and affordability for various inflammatory conditions.

Explore the critical need for diversity in hidradenitis suppurativa clinical trials to address health inequities and improve patient outcomes.

Ixekizumab shows promise in restoring clinical response for hidradenitis suppurativa patients previously unresponsive to adalimumab, highlighting new treatment options.

A cross-sectional survey revealed that many patients with HS are dissatisfied with treatment options, with gaps in knowledge about FDA-approved therapies.